Alaunos Therapeutics, Inc.: net property, plant and equipment
Net property, plant and equipment for Alaunos Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Alaunos Therapeutics, Inc. financial histories
What this measure means
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 91,000 | USD | 2026-03-31 | 10-K · 0001193125-26-134720 |
| At date | 2024-12-31 | 0 | USD | 2026-03-31 | 10-K · 0001193125-26-134720 |
| At date | 2023-12-31 | 2,000 | USD | 2025-03-31 | 10-K · 0000950170-25-047758 |
| At date | 2022-12-31 | 8,460,000 | USD | 2024-04-01 | 10-K · 0000950170-24-038868 |
| At date | 2021-12-31 | 10,941,000 | USD | 2023-03-07 | 10-K · 0000950170-23-006377 |
| At date | 2020-12-31 | 10,231,000 | USD | 2022-03-30 | 10-K · 0000950170-22-004972 |
| At date | 2019-12-31 | 1,110,000 | USD | 2021-03-01 | 10-K · 0001193125-21-063387 |
| At date | 2018-12-31 | 1,097,000 | USD | 2020-03-02 | 10-K · 0001193125-20-058863 |
| At date | 2017-12-31 | 1,211,000 | USD | 2019-03-05 | 10-K · 0001193125-19-063978 |
| At date | 2016-12-31 | 843,000 | USD | 2018-03-01 | 10-K · 0001193125-18-067077 |
| At date | 2015-12-31 | 581,000 | USD | 2017-02-16 | 10-K · 0001193125-17-046668 |
| At date | 2014-12-31 | 531,000 | USD | 2016-02-24 | 10-K · 0001193125-16-475875 |
| At date | 2013-12-31 | 801,000 | USD | 2015-02-26 | 10-K · 0001193125-15-065956 |
| At date | 2012-12-31 | 1,994,000 | USD | 2014-03-03 | 10-K · 0001193125-14-080282 |
| At date | 2011-12-31 | 1,141,000 | USD | 2013-03-18 | 10-K · 0001193125-13-112464 |
| At date | 2010-12-31 | 253,000 | USD | 2012-02-29 | 10-K · 0001144204-12-012003 |
Related financial histories
- Alaunos Therapeutics, Inc.: total assets
- Alaunos Therapeutics, Inc.: total liabilities
- Alaunos Therapeutics, Inc.: stockholders equity
- Alaunos Therapeutics, Inc.: cash and cash equivalents
- Alaunos Therapeutics, Inc.: net income or loss
- Alaunos Therapeutics, Inc.: operating cash flow
- Alaunos Therapeutics, Inc.: capital expenditure payments
- Alaunos Therapeutics, Inc.: revenue
- Alaunos Therapeutics, Inc.: contract revenue excluding tax
- Alaunos Therapeutics, Inc.: financing cash flow
- Alaunos Therapeutics, Inc.: investing cash flow
- Alaunos Therapeutics, Inc.: retained earnings or deficit
- Alaunos Therapeutics, Inc.: basic weighted-average shares
- Alaunos Therapeutics, Inc.: diluted weighted-average shares
- Alaunos Therapeutics, Inc.: basic earnings per share
- Alaunos Therapeutics, Inc.: diluted earnings per share
- Alaunos Therapeutics, Inc.: share-based compensation expense
- Alaunos Therapeutics, Inc.: operating income or loss
- Alaunos Therapeutics, Inc.: current assets
- Alaunos Therapeutics, Inc.: interest expense
- Alaunos Therapeutics, Inc.: current liabilities
- Alaunos Therapeutics, Inc.: current accounts payable
- Alaunos Therapeutics, Inc.: common-stock repurchase payments
- Alaunos Therapeutics, Inc.: operating expenses
- Alaunos Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Alaunos Therapeutics, Inc. / CIK 0001107421
- Captured
- 2026-09-20T05:23:32.946Z
- SEC response SHA-256
ceac768c7325f34d0f6470e00f80e7e6787b28f3ae115ba65aa7cdfdab90d956
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001107421.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))